Saturday 17 October 2026
Export STOK’s income statement to Excel — free account
Stoke Therapeutics, Inc.
STOK Healthcare Biotechnology
Stoke Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $184.4 million, up 404.5% from fiscal 2024. In the quarter to June 2026, revenue fell 32.5%, EPS fell 132.5% and free cash flow fell 129.0%, each against the same quarter a year earlier.
24.17
0.44
−1.79%
Follow STOK
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
32.64 | 0.00 | 0.00 | 0.00 |
P/S ratio |
6.70 | 10.19 | 64.01 | 78.30 | |
P/FCF ratio |
26.30 | 41.85 | 0.00 | 0.00 | |
P/Operating CF |
(45.36) | (61.72) | (33.89) | (38.17) | |
P/B ratio |
4.47 | 5.33 | 5.20 | 6.25 | |
Price to Tangible BV |
4.47 | 5.33 | 5.20 | 6.25 | |
EV/Sales |
5.49 | 8.65 | 53.30 | 67.68 | |
EV/EBITDA |
40.73 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
21.37 | 34.99 | (11.65) | (10.49) | |
EV/FCF |
21.56 | 35.51 | (11.58) | (10.33) | |
Quick Ratio |
6.21 | 5.06 | 8.57 | 7.19 | |
Current Ratio |
6.53 | 5.28 | 8.99 | 7.69 | |
Net Debt/EBITDA |
5.74 | 4.62 | 6.44 | 4.48 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.63 | 0.53 | 0.08 | 0.07 | |
Operating CF/Net income |
0.79 | 0.53 | 1.21 | 0.92 | |
Capex/Depreciation |
0.76 | 1.59 | (4.77) | (22.20) | |
Research and Development Expense of Revenue |
354.55% | 2,973.97% | 636.91% | 530.84% | |
Selling, General and Administrative Expense of Revenue |
150.74% | 1,508.27% | 320.66% | 270.81% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
75.61% | 702.43% | 140.52% | 115.84% | |
Graham Net Nets |
0.16 | 0.13 | 0.16 | 0.13 | |
Graham Number |
9.23 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
3.06% | (0.32%) | (8.72%) | (10.30%) | |
Free Cash Flow Yield |
3.80% | 2.39% | (7.19%) | (8.36%) | |
Revenue per Share |
0.18 | 0.02 | 0.10 | 0.14 | |
Operating CF per Share |
(0.52) | (0.51) | (0.96) | (0.86) | |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.03) | |
Free Cash Flow per Share |
(0.52) | (0.52) | (0.97) | (0.89) | |
Cash per Share |
4.24 | 4.81 | 5.45 | 4.44 | |
Shareholders Equity per Share |
5.26 | 5.95 | 6.26 | 5.23 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.26 | 5.95 | 6.26 | 5.23 | |
Free Cash Flow |
(30.50) | (30.69) | (60.93) | (58.56) | |
Working Capital |
230.71 | 247.83 | 325.88 | 280.61 | |
Capital Expenditures |
(0.13) | (0.23) | (0.35) | (1.98) | |
Net Current Asset Value |
220.28 | 239.72 | 318.28 | 274.12 | |
EV/EBIT |
41.52 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.17 | 0.06 | 0.21 | |
Price to Operating Income |
50.65 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
5.76 | 5.14 | 3.37 | 5.17 | |
Average Payables |
4.18 | 3.72 | 4.51 | 4.55 | |
Average Assets |
326.79 | 344.99 | 425.08 | 389.24 | |
Average Common Equity |
270.11 | 290.74 | 372.48 | 340.25 |
Columns are period end dates